AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2019
May 29, 2019
32870_dirs_2019-05-28_5efe9c95-274e-4e44-a6a5-0ddf1af94688.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2019-05-23
Reporting Person: Zoon Kathryn C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-23 | Common Stock | A | 5736 | — | Acquired | 24379 | Direct |
| 2019-05-28 | Common Stock | S | 1376 | $43.3884 | Disposed | 23003 | Direct |
Footnotes
F1: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan.
F2: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company.
F3: The sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon.
F4: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.04 to $43.58, inclusive.